Theravance Biopharma, Inc. (TBPH) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$16.94
Price Target
$27.00
Target Range
$14.00 — $40.00
Analyst Rating
Hold
Forward P/E6.7x
Trailing P/E-14.7x
Forward PEG—
Implied Growth+349.9%
Median Target$27.00
Analyst Spread96.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$14
-17.4%
Consensus
$27
+59.4%
Bull Case
$40
+136.1%
TBPH Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Theravance Biopharma, Inc. (TBPH) has a Wall Street consensus price target of $27.00, based on estimates from 16 covering analysts. With the stock currently trading at $16.94, this represents a potential upside of +59.4%. The company has a market capitalization of $858M.
Analyst price targets range from a low of $14.00 to a high of $40.00, representing a 96% spread in expectations. The median target of $27.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 6 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, TBPH trades at a trailing P/E of -14.7x and forward P/E of 6.7x. Analysts expect EPS to grow +349.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+36.4%
Avg Forward P/E12.3x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INVAInnoviva, Inc. | $1.9B | $22.52 | $37.67 | +67.3% | Buy | 11.8x | 10 |
 PRGOPerrigo Company plc | $1.7B | $12.26 | $20.00 | +63.1% | Hold | 5.8x | 36 |
 SUPNSupernus Pharmaceuticals, Inc. | $3.0B | $51.45 | $60.00 | +16.6% | Buy | 23.7x | 14 |
 PCRXPacira BioSciences, Inc. | $932M | $23.69 | $29.50 | +24.5% | Hold | 8.6x | 36 |
 INSMInsmed Incorporated | $29.1B | $137.09 | $217.11 | +58.4% | Buy | — | 35 |
 ARWRArrowhead Pharmaceuticals, Inc. | $11.1B | $79.14 | $81.22 | +2.6% | Buy | — | 20 |
 TPVGTriplePoint Venture Growth BDC Corp. | $226M | $5.57 | $8.95 | +60.7% | Hold | 6.0x | 12 |
 NKTRNektar Therapeutics | $1.7B | $85.09 | $132.83 | +56.1% | Buy | — | 33 |
 GSKGSK plc | $101.6B | $50.53 | $52.45 | +3.8% | Hold | 10.4x | 29 |
 JNJJohnson & Johnson | $541.3B | $224.62 | $249.27 | +11.0% | Buy | 19.4x | 40 |
Upside Potential Comparison
INVAPRGOTPVGINSMNKTRPCRXSUPNJNJSee TBPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TBPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TBPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTBPH — Frequently Asked Questions
Quick answers to the most common questions about buying TBPH stock.
What is the TBPH stock price target for 2026?
The consensus Wall Street price target for TBPH is $27, representing 59.4% upside from the current price of $16.94. With 16 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is TBPH a buy, sell, or hold?
TBPH has a consensus rating of "Hold" based on 16 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $27 implies 59.4% upside from current levels.
Is TBPH stock overvalued or undervalued?
With a forward P/E of 6.6606x, TBPH trades at a relatively low valuation. The consensus target of $27 implies 59.4% appreciation, suggesting meaningful undervaluation.
How high can TBPH stock go?
The most bullish Wall Street analyst has a price target of $40 for TBPH, while the most conservative target is $14. The consensus of $27 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover TBPH stock?
TBPH is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 7 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the TBPH stock forecast?
The 12-month TBPH stock forecast based on 16 Wall Street analysts shows a consensus price target of $27, with estimates ranging from $14 (bear case) to $40 (bull case). The median consensus rating is "Hold".
What is TBPH's forward P/E ratio?
TBPH trades at a forward P/E ratio of 6.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy TBPH stock?
Wall Street analysts are very optimistic on TBPH, with a "Hold" consensus rating and $27 price target (59.4% upside). 6 of 16 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do TBPH price targets vary so much?
TBPH analyst price targets range from $14 to $40, a 96% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $27 consensus represents the middle ground.